Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Nasus Pharma Ltd (NSRX) since 2026 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Nasus Pharma Ltd. Table 2 shows the detailed insider transactions. This company's CIK number is 2029039.
Total stock buying since 2026: $30,600.
Total stock sales since 2026: $0.
Total stock option exercises since 2026: $0.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2026 | 15,000 | $30,600 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2026-03 | 15,000 | $30,600 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2026-03-31 | Teleman Dan Benjamin (Chief Executive Officer) | Buy | 15,000 | 2.04 | 30,600 |
Insider trading activities including stock purchases, stock sales, and option exercises of NSRX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Nasus Pharma Ltd (symbol NSRX, CIK number 2029039) see the Securities and Exchange Commission (SEC) website.